Alpha 2.0
Login Register
» Journals » Leuk Lymphoma

Leukemia & Lymphoma

Leukemia & Lymphoma is a renowned peer-reviewed medical journal that focuses on the latest research and advancements in the field of hematological malignancies. It covers a wide range of topics including diagnosis, treatment, and management of leukemia, lymphoma, myeloma, and related disorders. With its comprehensive and authoritative content, the journal serves as a valuable resource for clinicians, researchers, and healthcare professionals involved in the care of patients with blood cancers.
Details
Abbr. Leuk Lymphoma
Start 1989
End Continuing
Frequency Fourteen issues a year, 2019-
p-ISSN 1042-8194
e-ISSN 1029-2403
Country United States
Language English
Specialties Oncology
Hematology
Metrics
h-index / Ranks: 3004 102
SJR / Ranks: 5368 790
CiteScore / Ranks: 6699 4.00
JIF / Ranks: 4138 2.6
Recent Articles
1.
Twice the trouble, half the fun: twin study suggests future direction for young adults with Hodgkin lymphoma
Daunov M, Deng C
Leuk Lymphoma . 2025 Mar; :1-3. PMID: 40085796
No abstract available.
2.
Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers
Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon C, et al.
Leuk Lymphoma . 2025 Mar; :1-3. PMID: 40080662
No abstract available.
3.
Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome
Bischof L, Ussmann J, Platzbecker U, Jentzsch M, Franke G
Leuk Lymphoma . 2025 Mar; :1-14. PMID: 40072896
Despite the vast heterogeneity of myelodysplastic neoplasm (MDS), treatment options are limited and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative approach. While, subsequently, allo-HSCT is the...
4.
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults
Amrein P, Preffer F, Fell G, Attar E, Narayan R, Blonquist T, et al.
Leuk Lymphoma . 2025 Mar; :1-11. PMID: 40070233
Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical...
5.
Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate
Stewart C, Owen C, Street L, Hay K, Perry S, Duggan P, et al.
Leuk Lymphoma . 2025 Mar; :1-4. PMID: 40067967
No abstract available.
6.
Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial
Pemmaraju N, Konopleva M, Sweet K, Stein A, Rizzieri D, Wang E, et al.
Leuk Lymphoma . 2025 Mar; :1-4. PMID: 40067964
No abstract available.
7.
Patient and care partner perspectives on treatment decision-making in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): a Global nLPHL One Working Group (GLOW) study
Major A, Palese M, Jones A, Goes M, Binkley M, Flerlage J, et al.
Leuk Lymphoma . 2025 Mar; :1-5. PMID: 40059593
No abstract available.
8.
Once weekly bortezomib decreases rates of peripheral neuropathy without diminishing efficacy as compared to twice weekly bortezomib in combination with lenalidomide, dexamethasone and daratumumab, a single center retrospective analysis
Gaspar E, Yi I, Bar N
Leuk Lymphoma . 2025 Mar; :1-4. PMID: 40059578
No abstract available.
9.
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study
Tucci A, Re A, Pagani C, Marcheselli L, Marcheselli R, Malaspina F, et al.
Leuk Lymphoma . 2025 Mar; :1-9. PMID: 40055982
The FIL_RECANZ (ClinicalTrials.gov: NCT02371161) is a prospective study evaluating salvage with autologous stem cell transplantation (ASCT) in aggressive B-cell lymphoma patients aged 65 - 75, fit according to the FIL...
10.
Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort
Kometas M, Hoff F, Hyak J, Irizarry-Gatell V, Marinos Velarde A, Jackson C, et al.
Leuk Lymphoma . 2025 Mar; :1-9. PMID: 40053838
Anemia leads to transfusion dependence and decreases quality of life in LR-MDS patients. Our study retrospectively evaluates the efficacy and safety of luspatercept in the real-world treatment of anemia in...